High Expression of BCL-2 and BCL-Xl in Diffuse Large B-Cell Lymphoma Confer Poor Prognosis but May Be Reversible by Combined Inhibition With Bet Inhibitors and Bh3 Mimetics.

Hematological Oncology- United Kingdom

doi 10.1002/hon.84_2629

Full Text

Abstract

Available in

Date

Authors

Publisher

Wiley

Related search

BCL-2 Protein Frequency in Patients With High-Risk Diffuse Large B-Cell Lymphoma

Sao Paulo Medical Journal
Medicine
2010English

Combination of BCL-2 and MYC Protein Expression Improves High-Risk Stratification in Diffuse Large B-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2015English

Frequent Expression of CD10 and BCL-6 in High-Grade Primary Extranodal Lymphoma With Diffuse Large B-Cell Lymphoma Morphology

Journal of clinical and experimental hematopathology : JCEH
Medicine
2004English

Combined Inhibition of Notch Signaling and BCL-2/BCL-xL Results in Synergistic Antimyeloma Effect

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

Apoptosis Is Augmented in High-Grade Serous Ovarian Cancer by the Combined Inhibition of BCL-2/BCL-xL and PARP

International Journal of Oncology
Cancer ResearchOncology
2017English

The BCL-2 Protein Family, BH3-mimetics and Cancer Therapy

Cell Death and Differentiation
Cell BiologyMolecular Biology
2015English

Combined MEK and BCL-XL Inhibition Kills KRAS -Mutant Cells

Cancer Discovery
Oncology
2012English

Structure-Based Design of Potent BCL-2/BCL-xL Inhibitors With Strong in Vivo Antitumor Activity

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2012English

Proteasome and HDAC Inhibition Changes the Expression Levels of BCL-2, BCL-Xl, Bim and Bik Proteins in Androgen-Independent PC-3 Cell Line

Gazi Medical Journal
Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy